2-(piperidin-1-yl)-5-methylthiazole

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(piperidin-1-yl)-5-methylthiazole
• 英文别名: 1-(5-methyl-thiazol-2-yl)-piperidine；1-(5-Methyl-thiazol-2-yl)-piperidin；5-Methyl-2-piperidin-1-yl-1,3-thiazole；5-methyl-2-piperidin-1-yl-1,3-thiazole
• 化学式: C₉H₁₄N₂S
• 分子量: 182.29
• InChiKey: IOLDMUSDTDNPBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  44.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(piperidin-1-yl)-5-methylthiazole 在 硫酸 、 三氧化硫 作用下， 生成 5-methyl-2-piperidino-thiazole-4-sulfonic acid
  参考文献：
  名称：

  Nagasawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 433,439; dtsch. Ref. S. 219, 223

  摘要：

  DOI：
• 作为产物：
  描述：

  哌啶 、 2-氯-5-甲基噻唑 在 吡啶 作用下， 生成 2-(piperidin-1-yl)-5-methylthiazole
  参考文献：
  名称：

  Nagasawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 433,439; dtsch. Ref. S. 219, 223

  摘要：

  DOI：

文献信息

• Synthesis of Unexpected Bifunctionalized Thiazoles by Nucleophilic Attack on Allenyl Isothiocyanate
  作者：Baker Jawabrah Al-Hourani、Frank Richter、Kai Vrobel、Klaus Banert、Marcus Korb、Tobias Rüffer、Bernhard Walfort、Heinrich Lang

  DOI：10.1002/ejoc.201301851

  日期：2014.5

  reactivity is also seen with N-aminophthalimide. In the presence of azide salt, hydrazoic acid, or N,N-disubstituted hydroxylamines, however, allenyl isothiocyanate is converted into bifunctionalized thiazoles. We explain the formation of these products by nucleophilic addition at the isothiocyanato moiety followed by ring closure and an N–N or N–O cleavage reaction to generate short-lived 2-imino-5-methylidenethiazole

  用各种亲核试剂处理异硫氰酸丙二烯酯会产生在 2 位具有官能团的 5-甲基噻唑。N-氨基邻苯二甲酰亚胺也观察到相同的反应模式。然而，在叠氮化物盐、偶氮酸或 N,N-二取代羟胺的存在下，异硫氰酸烯丙酯被转化为双官能化的噻唑。我们通过在异硫氰酸基部分亲核加成，然后闭环和 N-N 或 N-O 裂解反应来生成短寿命的 2-imino-5-methylidenethiazole 或 5-methylidenethiazol-2-one 来解释这些产物的形成。这些中间体通过加成反应被捕获以得到最终的杂环化合物。在 N,N-二取代羟胺的情况下，
• N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Ko Soo S.

  公开号：US20080132523A1

  公开（公告）日：2008-06-05

  The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药学上可接受的盐形式，用于预防哮喘和其他过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和动脉粥样硬化，包括其制备方法和中间体。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20100137299A1

  公开（公告）日：2010-06-03

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗和/或预防钠通道介导的疾病或症状，例如疼痛。
• SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
  申请人：Chafeev Mikhail

  公开号：US20120295897A1

  公开（公告）日：2012-11-22

  This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及螺环氧吲哚化合物，包括立体异构体、对映体、互变异构体或其混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。
• INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3885343A1

  公开（公告）日：2021-09-29

  The present disclosure provides compounds of Formula (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

  本公开提供了式（II）化合物。 本文所述化合物是组蛋白甲基转移酶（如泽斯特同源增强子 1 (EZH1) 和泽斯特同源增强子 2 (EZH2)）的抑制剂，可用于治疗和/或预防多种疾病（如增殖性疾病）。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。本公开还提供了鉴定EZH1和/或EZH2抑制剂的方法。